Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Biotech Representative Asks Legislature to Prepare for Possible FDA Approval of Synthetic Psilocybin
Senate Health & Welfare Committee · February 18, 2026
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
Summary
Tess Butler of Compass Pathways requested that the committee adopt language to allow timely state rescheduling and patient access to COM‑360 (synthetic psilocybin) if the FDA approves and the DEA reschedules the product.
Tess Butler, associate director of government affairs for Compass Pathways, told the Senate Health & Welfare Committee the company is conducting Phase 3 clinical trials of COM‑360, a synthetic, pharmaceutical‑grade psilocybin compound being evaluated for treatment‑resistant depression and PTSD.
"We are asking for your help to…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
30-day money-back on paid plans
